EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study

Hortensia Álvarez iD, Amanda Mocroft, Lene Ryom, Bastian Neesgaard, Simon Edwards, Veronica Svedhem, Huldrych F Günthard, Robert Zangerle, Colette Smith, Antonella Castagna, Antonella d'Arminio Monforte, Ferdinand Wit und 21 weitere

Clinical Infectious Diseases · 22.08.2023 · 77 (4) · 593-605

DOI: 10.1093/cid/ciad219 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.04.2023. Verfasst von Hortensia Álvarez und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Infectious Diseases Unit, Complexo Hospitalario Universitario de Ferrol, Ferrol, SERGAS-A Coruña, Spain. Hauptthemen laut MEDLINE: HIV Infections, HIV Integrase Inhibitors, HIV-1, RNA, Viral. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Austrian HIV Cohort Study, Australian HIV Observational Database.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact of different baseline variables in the RESPOND cohort.

Methods

We included treatment-naive participants aged ≥18 who initiated 3-drug ART, in 2014–2020. We assessed the odds of virological suppression (VS) at weeks 48 and 96 using logistic regression. Viral blips, low-level viremia (LLV), residual viremia (RV), and virological failure (VF) rates were assessed using Cox regression.

Results

Of 4310 eligible participants, 72% started integrase strand transfer inhibitor (INSTI)-based regimens. At 48 and 96 weeks, 91.0% and 93.3% achieved VS, respectively. At 48 weeks, Kaplan-Meier estimates of rates were 9.6% for viral blips, 2.1% for LLV, 22.2% for RV, and 2.1% for VF. Baseline HIV-1 RNA levels >100 000 copies/mL and CD4+ T-cell counts ≤200/µL were negatively associated with VS at weeks 48 (adjusted odds ratio, 0.51 [95% confidence interval, .39–.68] and .40 [.27–.58], respectively) and 96 and with significantly higher rates of blips, LLV, and RV. CD4+ T-cell counts ≤200/µL were associated with higher risk of VF (adjusted hazard ratio, 3.12 [95% confidence interval, 2.02–4.83]). Results were consistent in those starting INSTIs versus other regimens and those starting dolutegravir versus other INSTIs.

Conclusions

Initial high HIV-1 RNA and low CD4+ T-cell counts are associated with lower rates of VS at 48 and 96 weeks and higher rates of viral blips, LLV, and RV. Low baseline CD4+ T-cell counts are associated with higher VF rates. These associations remain with INSTI-based and specifically with dolutegravir-based regimens. These findings suggest that the impact of these baseline determinants is independent of the ART regimen initiated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV Integrase InhibitorsHIV-1RNA, ViralHumansCD4-Positive T-LymphocytesCohort StudiesProspective StudiesViral LoadViremia

Stichwörter der Autor:innen

blipintegrase inhibitorslow-level viremiaresidual viremiavirological failure

Substanzen

HIV Integrase InhibitorsRNA, Viral

Autor:innen und Institutionen

  • Department of Internal Medicine, Infectious Diseases Unit, Complexo Hospitalario Universitario de Ferrol, Ferrol, SERGAS-A Coruña, Spain.
  • Department of Biochemistry, Genetics and Immunology, Universidade de Vigo, Vigo, Spain.
  • CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.
  • Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark.
  • Department of HIV, Mortimer Market Centre, London, United Kingdom.

ORCID-Profile: Hortensia Álvarez, Melanie Stecher, Eva Poveda

Förderung

  • NIAID NIH HHS
  • Austrian HIV Cohort Study
  • Australian HIV Observational Database
  • CHU Saint-Pierre
  • University Hospital Cologne
  • EuroSIDA
  • Frankfurt HIV Cohort Study
  • Georgian National AIDS Health Information System

Zitieren

APA

Álvarez, H., Mocroft, A., Ryom, L., Neesgaard, B., Edwards, S., Svedhem, V., Günthard, H. F., Zangerle, R., Smith, C., Castagna, A., d'Arminio Monforte, A., Wit, F., Stecher, M., Lehman, C., Mussini, C., Fontas, E., González, E., Wasmuth, J. C., Sönnerborg, A., …, & RESPOND (International Cohort Consortium of Infectious Diseases) Study Group (2023). Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study. Clinical Infectious Diseases, 77(4), 593-605. https://doi.org/10.1093/cid/ciad219

Vancouver

Álvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, et al. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study. Clinical Infectious Diseases. 2023;77(4):593-605. doi:10.1093/cid/ciad219

BibTeX
@article{lvarez2023,
  author = {Álvarez, Hortensia and Mocroft, Amanda and Ryom, Lene and Neesgaard, Bastian and Edwards, Simon and Svedhem, Veronica and Günthard, Huldrych F and Zangerle, Robert and Smith, Colette and Castagna, Antonella and d'Arminio Monforte, Antonella and Wit, Ferdinand and Stecher, Melanie and Lehman, Clara and Mussini, Cristina and Fontas, Eric and González, Eva and Wasmuth, Jan-Christian and Sönnerborg, Anders and De Wit, Stéphane and Chkhartishvili, Nikoloz and Stephan, Christoph and Petoumenos, Kathy and Jaschinski, Nadine and Vannappagari, Vani and Gallant, Joel and Young, Lital and Volny Anne, Alain and Greenberg, Lauren and Martín-Iguacel, Raquel and Poveda, Eva and Llibre, Josep M and RESPOND (International Cohort Consortium of Infectious Diseases) Study Group, RESPOND (International Cohort Consortium of Infectious Diseases) Study Group},
  title = {Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {4},
  pages = {593--605},
  doi = {10.1093/cid/ciad219}
}
Kostenlos starten →